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ThE object of this study was to characterize the synthesis
and metabolism of platelet activating factor (PAF) by
intestinal mucosa subjected to ischaemia-reperfusion
injury. Canine intestinal mucosa produced 16:0-PAF,
18:0-PAF, and high levels of the corresponding lyso-
PAF metabolites. Three h of intestinal ischaemia and
ischaemia followed by I h of reperfusion did not affect
the synthesis or metabolism ofPAF by intestinal mucosa.
Intestinal mucosa elaborated a factor that rapidly
hydrolyzes PAF to lyso-PAF. The observed hydrolysis rate
was not altered by ischaemia or ischaemia and
reperfusion. In conclusion, this study suggests that intes-
tinal mucosa produces PAF and rapidly hydrolyzes PAF.
The PAF synthesis and metabolism rates of intestinal
mucosa is not altered by ischaemia reperfusion in this
model under the imposed conditions.
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Introduction
Intestinal ischaemia followed by reperfusion re-
suits in characteristic mucosal lesions. Increases in
microvascular permeability with transvascular move-
ment of fluid and macromolecules frequently occurs.
Although the mechanisms of ischaemic damage are
not completely understood, local inflammatory me-
diators have been implicated in the process. These
mediators include oxygen radicals, 1," eicosanoids
and platelet activating factor.4,5
Exogenous PAF increases intestinal capillary per-
meability and promotes leukocyte adhesion to the
post-capillary venous endothelium.6,7 Ischaemia-in-
duced changes in intestinal permeability are attenu-
ated by Ginko biloba extracts which contain PAF
receptor antagonist activity,
8 and synthetic PAF
receptor antagonists reduce the histological evi-
dence of ischaemic damage. Material extracted from
ischaemic intestinal tissue and extracts from post-
ischaemic venous blood have been reported to pos-
sess PAF-like activity in platelet aggregation assays.
Platelet aggregation assays, however, respond to
many pro-aggregatory mediators and stimuli, do not
provide insight into the chemical PAF species, and
do not detect biologically inactive PAF metabolites or
inactive PAF precursors. A large amount of indirect
and circumstantial evidence implicates PAF in
intestinal ischaemia-reperfusion injury, but direct
evidence of PAF production in these models
is not available, to the best of our knowledge.
Therefore, we characterized PAF synthesis and
metabolism by intestinal mucosa subjected
to ischaemia-reperfusion using physico-chemical
( 1994 Rapid Communications of Oxford Ltd
techniques, namely
spectrometry (GC-MS).
gas chromatography-mass
Materials and Methods
All experiments (n 8) were conducted using
anaesthetized dogs (sodium pentobarbitol, 30 mg/
kg, i.v.). Segments of the distal ileum were subjected
to 3 h of ischaemia by reducing the arterial perfusion
pressure to 30 mmHg followed by 1 h of reperfusion
under full aortic pressure. Samples of the mucosa
were obtained before induction of ischaemia, after
3 h of ischaemia, and after the 1 h reperfusion
period. About 300 mg of mucosal tissue was incubat-
ed in 2.5 ml Krebs buffer for 30 min and frozen until
PAF analysis. Mucosal PAF and lyso-PAF molecular
species were quantitated by stable isotope dilution
gas chromatography-negative ion chemical
ionization-mass spectrometry using deuterium la-
belled PAF as an internal standard. This technique
was developed in this laboratory and is described in
detail elsewhere. Blank samples containing no tis-
sue with only the internal standard were included in
all analyses. PAF and PAF metabolites were meas-
ured as the molecular ion of the pentafluorobenzoate
derivative. Lyso-PAF present in the samples was
further derivatized to the Sn-2 propionate derivative
as described previously.
Additional experiments were conducted to meas-
ure the capacity of the incubation media obtained
from normal and ischaemic intestinal tissue to
hydrolyze PAF to lyso-PAF. Incubation medium
(1 ml) was obtained at 30C and authentic 3H-
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labelled PAF (New England Nuclear, Boston, MA, H- ,a0 (A)
acetyl label) was added. The reaction mixture was
stopped at various times by the addition of 2 volumes
of methanol. Lipids, including PAF and lyso-PAF,
were extracted from the reaction mixture by the
Bligh-Dyer method for H-content and determined
by liquid sciutillation spectroscopy. Hydrolysis ofH-
acetyl PAF was determined as the late of loss of I-I
from the organic phase into the aqueous phase, into
which H-acetate partitions following enzymatic hy-
drolysis of the added H-PAF. Nonenzymatic hy-
drolysis in Krebs buffer not exposed to intestinal
tissue was determined and subtracted from all tissue
values. 700
Data are expressed as the mean _+ the standard
error of the mean and were analysed by analysis of
variance with BonFerroni’s test for multiple compari-
son of means. A p value of 0.05 was considered ._
statistically significant.
Results
The production of 16:0 PAF, 18:0 PAF, 16:0 lyso-
PAF, and 18:0 lyso-PAF by intestinal mucosa is
shown in Fig. 1. PAF synthesis was determined in
normal mucosa, ischaemic mucosa, and mucosa sub-
jected to ischaemia and reperfusion. Although syn-
thesis of PAF and lyso-PAF was clearly measurable,
no significant influence of ischaemia or reperfusion,
relative to non-ischaemic levels was observed. Inter-
estingly, statistically significantly higher (about 7-
fold) amounts of the corresponding 2-1yso-PAF
metabolite was detected in all mucosal tissue as-
sayed. The signal attributable to the 18:1-PAF deriva-
tive was also monitored, but this material was not
detected in any mucosal tissue samples. Clearly,
intestinal mucosa produces two 1-O-alkyl species of
PAF with the corresponding 2-1yso PAF metabolite
being far more abundant (7-fold). Furthermore, syn-
thesis of this mediator was not influenced by tissue
ischaemia or reperfusion.
Fig. 2 shows that intestinal mucosa liberates a
factor that rapidly hydrolysis exogenous PAF to
lyso-PAF. Incubation media that did not contain
intestinal, mucosa (tissue blank) hydrolyzed PAF to
< 5% indicating that the activity was derived from the
tissue. This tissue-derived factor released into
the incubation media is presumed to be the
enzyme PAF acetyl hydrolase. These data also
indicate that media derived from ischaemic tissue or
from tissue after reperfusion hydrolyze PAF rapidly
but not at a different rate than normal mucosa.
These data are consistent with the PAF and lyso-PAF
levels measured in normal and ischaemic intestinal
mucosa (Fig. 1). Lyso-PAF was more predominant
than was PAF, and production rates of both PAF
and lyso-PAF were independent of ischaemia and
reperfusion.
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FIG. 1. Synthesis of various molecular species of PAF and lyso-PAF by
intestinal mucosal tissue before ischaemia, after 3 h ischaemia, and after
h reperfusion. All analytes were measured by stable isotope dilution GC/
MS as described in Methods. All results are mean + S.E.M., n 8. Note the
dramatic differences in the scales of the upper panel (PAF) and the lower
panel (lyso-PAF). Panel (A): rl, 16:0 PAF; I, 18:0 PAF. Panel (B): I-’l, 16:0
lyso-PAF; !, 18:0 lyso-PAF.
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FIG. 2. The rate of PAF hydrolysis to lyso-PAF of incubation media obtained
from incubations containing intestinal tissue before ischaemia, after 3 h
ischaemia, and after reperfusion. Nonspecific PAF hydrolysis, calculated
from the hydrolysis of PAF in media without intestinal tissue, was less than
5% and has been subtracted from the rates shown for intestinal tissue,
n 8, Key: (O), before ischaemia; (o), ischaemia; (/k), reperfusion.
Discussion
This study uses sensitive GC/MS techniques to
characterize PAF synthesis and metabolism in intes-
tinal mucosal tissue subjected to ischaemia-
reperfusion injury. The results clearly indicate that
intestinal mucosa synthesize PAF and, to a much
greater extent, lyso-PAF. However, the production
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of PAF was not affected by ischaemia or
ischaemia-reperfusion in this particular setting. Also,
mucosal tissue very rapidly inactivates PAF to lyso-
PAF at equal rates in normal and ischaemic intestine.
The time frame of PAF synthesis and metabolism
in intestinal ischaemia-reperfusion injury should be
considered. This study examined mucosal synthesis
and metabolism of PAF after 1 h of reperfusion.
Generally, it is recognized that reperfusion injury
following cellular ischaemia occurs shortly after the
reperfusion period. A 1 h post-reperfusion sampling
period was chosen in this study since significant
changes in mucosal arachidonate metabolism after
3h of intestinal ischaemia, and after l h of
reperfusion have been demonstrated previously in
this laboratory. The possibility that alterations in PAF
synthesis or metabolism occur at earlier or later time
points from the designed 1-h reperfusion sampling
period cannot be ruled out from this study, and
should be considered.
Intestinal ischaemia and reperfusion results in
cellular inflammation with the infiltration of neutroo
phils into the tissue. The synthesis of arachidonic
acid metabolites also increases after intestinal
ischaemia-reperfusion, suggesting a pro-inflamma-
tory role for lipid mediators in this condition. Since
arachidonic acid metabolism and PAF synthesis often
occur concomitantly, investigations directed at un-
derstanding an involvement of PAF in the functional
deterioration and cellular inflammation associated
with intestinal ischaemia-reperfusion has been un-
dertaken. Platelet activating factor administration
produces bowel necrosis and induces a condition
similar to splanchnic artery occlusion shock when
administered to experimental animals.1 Platelet acti-
vating factor is also involved in ischaemia-induced
adherence of leukocytes to post-capillary
endothelium in the small intestine. Also, a platelet
aggregating material has been extracted from cat
intestinal mucosa after ischaemia and reperfusion
and a similar aggregating material was obtained from
intestinal venous blood in dogs after reperfusion.
Taken together, these studies provide circumstantial
evidence that PAF is released during intestinal
ischaemia and that PAF may play a causal role in the
disease. The present data, however, do not indicate
any changes in mucosal PAF synthesis or metabolism
after intestinal ischaemia or reperfusion (Fig. 1). The
physico-chemical GC/MS methods used in this study
leave little room for error in interpreting the results,
unlike platelet aggregation bioassays. Ischaemia-
induced PAF synthesis was not observed in this
study, and may represent species differences or the
methods used to induce splanchnic ischaemia in
other studies. Other studies linking intestinal
ischaemia with PAF, induce ischaemia indirectly,
often by administering other mediators such as tu-
mour necrosis factor, endotoxin,n and even PAF
itself.1 The involvement of PAF in these models of
intestinal ischaemia may, therefore, be secondary to
other factors inherent in the model itself. These
factors may include cytokine or LPS-induced PAF
synthesis by resident cells in the gut. Therefore,
intestinal ischaemia-reperfusion injury can result
from many causes, some may stimulate intestinal PAF
synthesis while others do not. This study indicates
that the mechanical obstruction of blood flow to the
small intestine does not influence the rate of PAF
synthesis or metabolism in this model.
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